Drug control of solid tumour metastases: A critical view

Anticancer Research

Volumn 19, Issue 2 A, 1999, Pages 1117-1124

  Sava, Gianni ^a,b   Bergamo, Alberta ^a  

^a Callerio Foundation   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Drug; Metastasis; Treatment

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIMETASTATIC AGENT; BATIMASTAT; CICAPROST; CYTOSTATIC AGENT; CYTOTOXIC AGENT; NAMI A; RAZOXANE; RUTHENIUM COMPLEX; TRIAZENE DERIVATIVE; UNCLASSIFIED DRUG;

BONE MARROW TOXICITY; EXPERIMENTAL NEOPLASM; HUMAN; LEUKEMIA; LUNG METASTASIS; METASTASIS; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; EPOPROSTENOL; HUMANS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PHENYLALANINE; RAZOXANE; RUTHENIUM; THIOPHENES;

EID: 0032993805     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Aslakson CJ and Miller FR: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52: 1399-1405, 1992.
2. Leibovici J, Klorin G, Huszar M, Hoenig S and Michowitz M: Differential sensitivity to hypertermia of the F1 and F10 B16 melanoma variants. Int J Exp Path 72: 139-150, 1991.
3. Liotta LA and Stetler-Stevenson WG: Principles of molecular cell biology of cancer: cancer metastasis. In: Cancer: Principles and Practice of Oncology (DeVita VT, Hellman S and Rosenberg SA, eds), 4th Ed., Philadelphia, JB. Lippencott Co., 1993, pp 134-149.
4. Dickson RB, Johnson MD, Maemura M and Low J: Anti-invasion drugs. Breast Cancer Research and Treatment 38: 121-132, 1996.
5. Rak J, Kusnierczyk H, Strzdala L, Klosiewicz S and Radzikowski C: Transplantable mouse mammary adenocarcinoma 16/C as a model in experimental cancer therapy. III. Sensitivity to antitumor drugs. Archivum Immunologiae et Therapiae Experimental 37: 389-397, 1989.
6. Hurford RK Jr, Dranoft G, Mulligan RC and Tepper RJ: Gene therapy of metastatic cancer in vivo retroviral gene targeting. Nature Genetics 10: 430-435, 1995.
7. Arca MJ, Mule JJ and Chang AE: Genetic approaches to adoptive cellular therapy of malignancy. Seminars in Oncology 1: 108-117, 1996.
8. Taneja SS, Pang S, Cohan P and Belldegrun A: Gene therapy: principles and potential. Cancer Surveys 23: 247-266, 1995.
9. Porgador A, Feldman M and Eisenbach L: Immunotherapy of tumor metastasis via gene therapy. Nat Immun 13: 113-130, 1994.
10. Goldfarb RH, Whiteside TL, Basse Per H, Lin W-C, Vujanovic N and Herberman RB: Natural killer cells and gene therapy: potential of gene transfections for optimizing effector cell functions and for targeting gene products into tumor metastases. Nat Immun 13: 131-140, 1994.
11. Brunda MJ, Luistro L, Rumennik L, Wright RB, Dvorozniak M, Aglione A, Wigginton JM, Wiltrout RH, Hendrzak JA and Palleroni AV: Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother Pharmacol 38: S16-S21, 1996.
12. Gasparini G and Harris AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. Journal of Clinical Oncology 13: 765-782, 1995.
13. Greig RG and Trainer DL: Shaping future strategies fo,r the pharmacological control of tumor cell metastases. Cancer and Metastasis Reviews 5: 3-14, 1986.
14. Konety BR and Getzenberg RH: Novel therapies for advanced prostate cancer. Seminars in Urologic Oncology 15: 33-42, 1997.
15. Smyth JF: Cancer genetics and cell and molecular biology. Is this the way forward? CHEST 109: 125S-129S, 1996.
16. Piccart MJ and Hortobagyi GN: Conclusions: future strategies in the treatment of breast cancer. Seminars in Oncology 24: S3-34-S3-40, 1997.
17. Hellmann K: Razoxane, metastasis and adjuvant chemotherapy. Clin Expl Metastasis 5: 1-2, 1987.
18. Humphries MJ, Matsumoto K, White SL, Molyneux RJ and Olden K: Augmentation of murine natural killer cell activity by Swainsonine, a new antimetastatic immunomodulator. Cancer Research 48: 1410-1415, 1988.
19. Itoh H, Noda H, Amano H and Ito H: Immunological analysis of inhibition of lung metastases by fucoidan (GIV-A) prepared from brown seaweed Sargassum Thunbergii. Anticancer Research 15: 1937-1948, 1995.
20. Welch DR, Harper DE and Yohem KH: U-77,863: a novel cinnamide isolated from Streptmyces grieoluteus that inhibits cancer invasion and metastasis. Clin Expl Metastasis 11: 201-212, 1993.
21. Ito H, Ito H, Amano H and Noda H: Inhibitory effect of a biscoclaurine alkaloid, cepharanthin, on lung metastasis of Lewis lung carcinoma. Japan J Pharmacol 56: 195-202, 1991.
22. Sola F, Farao M, Ciomei M, Pastori A, Mongelli N and Grandi M: FCE 27266, a sulfonic distamycin derivative, inhibits experimental and spontaneous lung and liver metastasis. Invasion Metastasis 15: 222-231, 1995.
23. Humphries MJ, Matsumoto K, White SL and Olden K: Inhibition of experimental metastasis by castanospermine in mice: blockage of two distinct stages of tumor colonization by oligosaccharide processing inhibitors. Cancer Research 46: 5215-5222, 1986.
24. Christian MC, Pluda JM, Ho PTC, Arbuck SG, Murgo AJ and Sausville EA: Promising new agents under development by the division of cancer treatment, diagnosis, and centers of the National Cancer Institute. Seminars in Oncology 24: 219-240, 1997.
25. Lonn U, Lonn S, Nilsson B and Stenkvist B: Prognostic significance of c-erb-B2 amplification in fine-needle biopsies of breast cancer patients not operated at diagnosis. Breast Cancer Res Treat 39: 213-220, 1996.
26. Worsley SD, Ponder BA and Davies BR: Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol 64: 189-195, 1997.
27. Zhau HY, Zhou J, Symmans WF, Chen BQ, Chang SM, Sikes RA and Chung LW: Transfected neu oncogene induces human prostate cancer metastasis. Prostate 28: 73-83, 1996.
28. Montesano R, Hollstein M and Hainaut P: Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer 69: 225-235, 1996.
29. Sheyn I, Noffsinger AE, Heffelfinger S, Davies B, Miller MA and Fenoglio Preiser CM: Amplification and expression of the cyclin D1 gene in anal and esophageal squamous cell carcinomas. Hum Pathol 28: 270-276, 1997.
30. Duenas Gonzalez A, Isales CM, del Mar Abad Hernandez M, Gonzalez Sarmiento R, Sangueza O and Rodriguez Commes J: Expression of inducible nitric oxide synthase in breast cancer correlates with metastatic disease. Mod Pathol 10: 645-649, 1997.
31. Streit M, Schmidt R, Hilgenfeld RU, Thiel E and Kreuser ED: Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors. J Mol Med 74: 253-268, 1996.
32. Shimazui T, Bringuier PP, van Berkel H, Akaza H, Debruyne FM, Oosterwijk E and Schalken JA: Decreased expression of alpha-catenin is associated with poor prognosis of patients with localized renal cell carcinoma; Int J Cancer 74: 523-528, 1997.
33. Froggat NJ, Brasset C, Koch DJ, Evaps DG, Hodgson SV, Ponder BA and Maher ER: Mutation screening of MSH2 and MLH1 mRNA in hereditary non-polyposis colon cancer syndrome. J Med Genet 33: 726-730, 1996.
34. Lowsky R, DeCoteau JF, Reitmair AH, Ichinohasama R, Dong WF, Xu Y, Mak TW, Kadin ME and Minden MD: Defects of the mismatch repair gene MSH2 are implicated in the development of murine and human lymphoblastic lymphomas and are associated with the aberrant expression of rhombotin-2 (Lmo-2) and Ta1-1 (SCL). Blood 89: 2276-2282, 1997.
35. Cheng AJ, Tang R, Wang JY, See LC and Wang TC: Possible role of telomerase activation in the cancer predisposition of patients with hereditary nonpolyposis colorectal cancers. J Natl Cancer Inst 90: 316-321, 1998.
36. Sarraf CE and Bowen ID: Proportions of mitotic and apoptotic cells in a range of untreated experimental tumours. Cell and Tissue Kinetics 21: 45-49, 1988.
37. Moore JV: Death of cells and necrosis of tumours. In: Perspectives in mammalian cell death (Potten CS, ed). Oxford, Oxford University Press, 1987 pp 295-325.
38. Paget S: The distribution of secondary growths in cancer of the breast. The Lancet i: 571-573, 1889.
39. Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, De Clerck YA and Mundy GR: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the biphosphonate ibandronate and tissue inhibitor of the matrix metallo proteinase-2. J Clin Invest 99: 2509-2517, 1997.
40. Sledge GW, Qulali M Jr, Goulet R, Bone EA and Fife R: Effect of matrix metalloproteinase inhibitor Batimastat on breast cancer regrowth and metastasis in athymic mice. J Nat Cancer Inst 87: 1546-1550, 1995.
41. Fazioli F and Blasi F: Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? TiPS 15: 25-29, 1994.
42. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA and Levinson AD: Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci 90: 5021-5025, 1993.
43. Kobayashi H, Shinohara H, Gotoh J, Fujie M, Fujishiro S and Terao T: Anti-metastatic therapy by urinary trypsin inhibitor in combination with an anti-cancer agent. British J Cancer 72: 1131-1137, 1995.
44. Dumont JA, Jones Jr WD and Bitonti AJ: Inhibition of experimental metastasis and cell adhesion of B16F1 melanoma cells by inhibitors of protein kinase C. Cancer Res 52: 1195-1200, 1992.
45. Schwartz GK, Haimovitz-Friedman A, Dhupar SK, Ehleiter D, Maslak P, Lai L, Loganzo F Jr, Kelsen DP, Fuks Z and Albino AP: Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor Safingol in mitomycin C-treated gastric cancer cells. J Nat Cancer Ins 87: 1394-1399, 1995.
46. Nagabuchi E, VanderKolk WE, Une Y and Ziegler MM: TNP-470 antiangiogenic therapy for advanced murine neuroblastoma. J Pediatric Surg 32: 287-293, 1997.
47. Schneider MR, Schirner M, Lichtner RB and Graf H: Antimetastatic action of the prostacyclin analogue cicaprost in experimental mammary tumours. Breast Cancer Res Treatment 38: 133-141, 1996.
48. Davies B, Brown PD, East N, Crimmin MJ and Balkwill FR: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenograft. [published erratum appears in Cancer Res. 53: 3652, 1993]. Cancer Res 53: 2087-2091, 1993.
49. Schneider MR and Schirner M: Antimetastatic prostacyclin analogs. Drugs Future 18: 29-48, 1993.
50. Honn KV, Tang DG and Chen YQ: Platelets and cancer metastasis: more than an epiphenomenon. Semin Thromb Hemost 18: 392-415, 1992.
51. Schneider MR, Tang DG, Schirner M and Honn KV: Prostacyclin and its analogues: antimetastatic effects and mechanism of action. Cancer Met Rev 13: 349-364, 1994.
52. Schirner M and Schneider MR: Cicaprost inhibits metastases of animal tumours. Prostaglandins 42: 451-461, 1992.
53. Schirner M and Schneider MR: The stable prostacyclin analogue Cicaprost inhibits metastasis of tumors of R3327 MAT Lu prostate carcinoma and SMT 2A mammary carcinoma. J Cancer Res Clin Oncol 118: 497-501, 1992.
54. Schirner M, Lichtner RB and Schneider MR: The stable prostacyclin analogue Cicaprost inhibits metastasis to lungs and lymph nodes in the 13762NF MTLn3 rat mammary carcinoma. Clin Expl Metast 12: 24-30, 1994.
55. rd Int. Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation & Radiation Injury. Washington DC, Oct. 13-16, 1993.
56. Lichtner RB, Hutchinson G, Wedderburn N and Hellmann K: Antiplatelet pyrimido-pyrimidines and metastasis. Cancer Treatment Reviews 12: 221-234, 1985.
57. Gescher A: Towards selective pharmacological modulation of protein kinase C-opportunities for the development of novel antineoplastic agents. Br J Cancer 66: 10-19, 1992.
58. Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Testa N, Stern P, McDermott R, Potter M and Pettit GR: A Phase I study of intravenous bryostatin-1 in patients with advanced Icancer. Br J Cancer 68: 418-424, 1993.
59. Akinaga S, Gomi K, Morimoto M, Tamaoki T and Okabe M: Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 51: 4888-4892, 1991.
60. Seynaeve CM., Kazanietz MG., Blumberg PM., Sausville EA and Worland PJ: Dfflerential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. Mol Pharmacol 45: 1207-1214, 1994.
61. LeServe AW and Hellmann K: Metastases and the normalization of tumour blood vessels by ICRF159: a new type of drug action. British MedJ 1: 597-601, 1972.
62. Creech RH, Engstrom PF, Harris DT, Catalano RB and Bellet RE: Phase II study of ICRF-159 in refractory metastatic breast cancer. Cancer Treat Rep 63: 111-114, 1979.
63. Hellmann K, Gilbert J, Evans M, Cassel P and Taylor R: Effect of razoxane on metastases from colorectal cancer. Clin Expl Metastasis 5: 3-8, 1987.
64. Giraldi T and Sava G: Selective antimetastatic drugs (review). Anticancer Res 1: 163-164, 1981.
65. Giraldi T, Guarino AM, Nisi C and Sava G: Antitumor and antimetastatic effects of benzenoid triazenes in mice bearing Lewis lung carcinoma. Pharmacol Res Commun 12: 1-11, 1980.
66. Sava G, Giraldi T, Nisi C and Bertoli G: Prophylactic anti-metastatic treatment with aryldimethyltriazenes as adjuvants to surgical tumor removal in mice bearing Lewis lung carcinoma. Cancer Treat Rep 66: 115-120, 1982.
67. Sava G, Giraldi T, Lassiani L and Nisi C: Antimetastatic action and hematological toxicity of p-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt and 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide used as prophylactic adjuvants to surgical tumor removal in mice bearing B16 melanoma. Cancer Res 44: 64-68, 1984.
68. Sava G, Giraldi T, Zupi G and Sacchi A: Effects of antimetastatic dimethyltriazenes in mice bearing Lewis lung carcinoma lines with different metastatic potential. Invasion Metastasis 4: 171-178, 1984.
69. Sava G, Giraldi T, Bartoli-Klugmann F, Decorti G and Mallardi F: Effects of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt on leukemic infiltration of brain and liver in mice bearing P388 leukemia. Eur J Cancer Clin Oncol 20: 287-289, 1984.
70. Grill V, Mallardi F, Zorzet S, Perissin L and Giraldi T: Morphological analysis of metastatic potential and antimetastatic drug effects in mice bearing two lines of Lewis lung carcinoma. Clin Expl Metastasis 5: 233-244, 1987.
71. Nardelli B, Contessa AR, Romani L, Sava G, Nisi C and Fioretti MC: Immunogenic changes of murine lymphoma cells following in vitro treatment with aryl-triazene derivatives. Cancer Immunol Immunother 16: 157-161, 1984.
72. Nardelli B, Puccetti P, Romani L, Sava G, Bonmassar E and Fioretti MC: Chemical xenogenisation of murine lymphoma cells with triazene derivatives: immunotoxicological studies. Cancer Immunol Immunother 17: 213-217, 1984.
73. Giraldi T, Sava G, Mitri E and Cherubino R: Hemostasis and mechanism of action of selective antimetastatic drugs in mice Lewis lung carcinoma. Eur J Cancer Clin Oncol 20: 961-966, 1984.
74. 4(DMSO)Im], a metal complex of ruthenium with anti-metastatic properties. Clin Expl Metastasis 10: 273-280, 1992.
75. 4 (DMSO) Im] on solid mouse tumors. Anti-cancer Drugs 3: 25-31, 1992.
76. Mestroni G, Alessio E, Sava G, Pacor S, Coluccia M and Boccarelli A: Water-soluble ruthenium(III)-dimethyl-sulfoxide complexes: chemical behaviour and pharmacological properties. Metal Based Drugs 1: 41-63, 1993.
77. 4(DMSO)Im] in the mouse. Clin Expl Metastasis 12: 93-100, 1994.
78. 4(DMSO)Im]. Selective inhibition of spontaneous lung metastases by the ruthenium complex. Drug Invest 8: 150-161, 1994.
79. Sava G, Pacor S, Bergamo A, Cocchietto M, Mestroni G and Alessio E: Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition. Chem-Biol Interact 95: 109-126, 1995.
80. Sava G, Capozzi I, Clerici K, Gagliardi R, Alessio E and Mestroni G: Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex. Clin Expl Metastasis 16: 371-379, 1998.
81. Sava G, Capozzi I, Bergamo A, Gagliardi, Cocchietto M, Masiero L, Onisto M, Alessio E, Mestroni G and Garbisa S: Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an antimetastatic ruthenium complex. Int J Cancer 68: 60-66, 1996.
82. 4(DMSO)Im] and ruthenium uptake by tumour cells, Anticancer Drugs 7: 697-702, 1996.
83. Welch DR: Technical considerations for studying cancer metastasis in vivo. Clin Expl Metastasis 15: 272-306, 1997.